Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound used for manufacturing auxiliary therapeutic agent for chemotherapy cancer patient

A technology of adjuvant therapy and composition, applied in the direction of drug combination, medical raw materials derived from algae, medical raw materials derived from fungi, etc., can solve problems such as numbness of extremities, poor blood circulation, and low quality of life

Inactive Publication Date: 2015-03-18
MICROBIO CO LTD
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs have toxic side effects, including fever, nausea, vomiting, diarrhea, bone marrow suppression, numbness in extremities, and poor blood circulation
Patients often have poor quality of life or even life-threatening complications due to symptoms of drug-induced side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound used for manufacturing auxiliary therapeutic agent for chemotherapy cancer patient
  • Compound used for manufacturing auxiliary therapeutic agent for chemotherapy cancer patient
  • Compound used for manufacturing auxiliary therapeutic agent for chemotherapy cancer patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Inhibition of abnormal fossa (ACF) induced by 1,2-dimethylhydrazine (DMH)

[0045] 1.1 Materials and methods

[0046] Animal research is approved by the Laboratory Animal Management and Use Committee of National Taiwan University, and all animals are handled in accordance with the standard guidelines for the care and use of laboratory animals. F344 male rats about 6 weeks old were purchased from the Laboratory Animal Center of National Taiwan University School of Medicine.

[0047] Male F344 rats were randomly divided into groups by weight, with 8 rats in each group. In the first week after adaptation, rats were fed Harlan AIN-76 purified rodent diet containing 17.7% by weight protein, 64.9% carbohydrate and 5.2% fat (Harlan AIN-76 purified rodent diet, Indiana, USA Harlan Laboratory, Indianapolis) (Harlan AIN-76 purified food rodent feed information page, http: / / www.harlan.com / download.axd / 1131a6e1617348b9a99c8d2af933f796.pdf?d=170481). The rats were kept in sta...

Embodiment 2

[0073] Example 2: Inhibition of colorectal cancer caused by the formation of 1,2-dimethylhydrazine (DMH)

[0074] 2.1 Materials and methods

[0075] The purchased F344 male rats aged about 6 weeks were randomly divided into groups after one week of adaptation. There are 30 animals in each group. The animals were divided into the following groups: C1 group: injection 1,2-dimethylhydrazine (DMH) control group; C2 group: normal saline injection control group; B2 group: taking a middle dose of the six-component formula of the present invention (34.6 mg / rat / Days) Experimental group. DMH was dissolved in brine (0.9% NaCl solution) to form a 2% solution. The pH was adjusted to 6.7, then aliquoted and stored at -20°C until needed. DMH was injected intraperitoneally (IP) at a dose of 30 mg / kg every week for 8 weeks (equivalent to an injection of 1.5 ml of 2% solution per kg body weight). The control group was injected with normal saline (1.5 ml saline per kg body weight). See Table 6 ...

Embodiment 3

[0095] Example 3: Reduce the volume of mouse colorectal cancer and prolong animal survival

[0096] 3.1 Materials and methods

[0097] Male BALB / c mice were purchased from the National Laboratory Animal Center in Taiwan, and maintained at 21±2°C in a 12-hour light / dark cycle. AIN-76 purified feed and distilled water are freely consumed by mice.

[0098] The mice were randomly divided into 7 groups, with 12 mice in each group and 3 mice in each cage. The mouse colon cancer cell line CT-26-VD is prepared in complete Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (Dulbecco's Modified Eagle Medium (DMEM); GIBCO, catalog number 11995) at 37°C Incubate in an incubator containing 5% carbon dioxide. The establishment of a mouse colon cancer model has been described previously (Wittke M et al., Int J Radiat Oncol Biol Phys 2014; 88:1188-95). Briefly, mice were weighed and anesthetized with an appropriate dose of sodium pentobarbital (Somnotol, Canada, 10 μl / g, 6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound used for manufacturing an auxiliary therapeutic agent for chemotherapy cancer patients; the compound mainly comprises fermentation soybean abstract, green tea abstract, spirulina, turmeric abstract, antrodia mycelium, and grape seed abstract; the compound can prevent colorectal polyps from canceration, and improves chemotherapy effect, prolongs cancer patient survival period, and reduces non-deteriorate survival period / and chemotherapy side effects; the compound also provides anti-inflammation activity, and effectively reduces generation of inflammation mediums like PGE2, NO, -alpha (TNF-alpha) and -6(IL-6).

Description

[0001] Related applications [0002] This case claims the priority of Taiwan Patent Application No. 102132310 filed on September 6, 2013, which is incorporated herein by reference in its entirety. Technical field [0003] The present invention relates to a composition for manufacturing an adjuvant therapeutic agent for chemotherapy. Specifically, the present invention relates to a composition for manufacturing an adjuvant therapeutic agent for cancer patients undergoing chemotherapy, which can effectively inhibit the proliferation and canceration of colorectal polyps, improve the effect of chemotherapy, improve chemotherapy compliance and reduce chemotherapy side effects. Background technique [0004] Fermented soybean products, green tea, spirulina, turmeric, Antrodia camphorata and grape seeds are all natural health treasures, and some biochemical tests have shown that each of the above substances has a health effect on the human body. The main pharmacological activity of curcumi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9066A61P35/00A61P29/00
CPCA61K36/9066A61K35/748A61K36/07A61K36/48A61K36/82A61K36/87A61K2236/30A61K2236/19A23V2002/00A61K2300/00A23V2200/30A23V2250/206A23V2250/21A23V2250/208A23V2250/708A61K36/05A23V2200/308
Inventor 路孔明
Owner MICROBIO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com